Authors

Daniel A. Arber, University of Chicago, Chicago, IL
Attilio Orazi, Texas Tech University Health Sciences Center El Paso, El Paso, TX
Robert P. Hasserjian, Massuchusetts General Hospital, Boston, MA
Michael J. Borowitz, Johns Hopkins University, Baltimore, MD.
Katherine R. Calvo, Johns Hopkins University, Baltimore, MD.
Hans-Michael Kvasnicka, Helios Universitätsklinikum Wuppertal, Wuppertal, Germany
Sa A. Wang, University of Texas MD Anderson Cancer Center, Houston, TX
Adam Bagg, University of Pennsylvania, Philadelphia, PA
Tiziano Barbui, Clinical Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy
Susan Branford, Centre for Cancer Biology, Adelaide, SA, Australia
Carlos E. Bueso-Ramos, University of Texas MD Anderson Cancer Center, Houston, TX
Jorge E. Cortes, Georgia Cancer Center, Augusta, GA
Paola Dal Cin, Brigham and Women's Hospital, Boston, MA
Courtney E. DiNardo, University of Texas MD Anderson Cancer Center, Houston, TX
Hervé Dombret, Université Paris Cité, Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris, Paris, France
Eric J. Duncavage, Washington University in St Louis, St. Louis, MO
Benjamin L. Ebert, Dana-Farber Cancer Institute, Boston, MA
Elihu H. Estey, University of Washington, Seattle, WA
Fabio Facchetti, University of Brescia School of Medicine, Brescia, Italy
Kathryn Foucar, University of New Mexico, Albuquerque, NM
Naseema Gangat, Mayo Clinic, Rochester, MN
Umberto Gianelli, Università degli Studi di Milano, Milan, Italy.
Lucy A. Godley, University of Chicago, Chicago, IL
Nicola Gökbuget, Goethe University, Frankfurt, Germany
Jason Gotlib, Stanford University School of Medicine, Stanford, CA.
Eva Hellström-Lindberg, Karolinska Institutet, Solna, Sweden
Gabriela S. Hobbs, Massuchusetts General Hospital, Boston, MA
Ronald Hoffman, Mount Sinai Medical Center, New York, NY
Elias J. Jabbour, University of Pennsylvania, Philadelphia, PA
Jean-Jacques Kiladjian, Université Paris Cité, Hôpital Saint-Louis, Assistance Publique - Hôpitaux de Paris, Paris, France
Richard A. Larson, University of Chicago, Chicago, IL
Michelle M Le Beau, University of Chicago, Chicago, IL
Mignon L-C Loh, Seattle Children's Hospital, Seattle, WA
Bob Löwenberg, Erasmus Medical Center, Rotterdam, Netherlands
Elizabeth Macintyre, Université Paris Cité, Paris, France.
Luca Malcovati, University of Pavia, Pavia, Italy
Charles G. Mullighan, St. Jude Children's Research Hospital, Memphis, TN
Charlotte Niemeyer, University of Freiburg Medical Center, Freiburg um Breisgau, Germany.
Olatoyosi M. Odenike, University of Chicago, Chicago, IL.
Seishi Ogawa, Kyoto University, Kyoto, Japan
Alberto Orfao, University of Salamanca, Salamanca, Spain
Elli Papaemmanuil, Memorial Sloan-Kettering Cancer Center, New York, NY.
Francesco Passamonti, University of Pavia, Pavia, Italy
Kimmo Porkka, Helsinki University Central Hospital Comprehensive Cancer Center, Helsinki, Finland
Ching-Hon Pui, St. Jude Children's Research Hospital, Memphis, TN.
Jerald P. Radich, Fred Hutchinson Cancer Research Center, Seattle, WA
Andreas Reiter, University Hospital Mannheim, Mannheim, Germany
Maria Rozman, University of Barcelona, Barcelona, Spain
Martina Rudelius, Ludwig Maximilians University Munich, Munich, Germany.
Michael R. Savona, Vanderbilt University School of Medicine, Nashville, TN.
Annette Schmitt-Graeff, Albert-Ludwigs-University Freiburg, Freiburg im Breisgau, Germany
Akiko Shimamura, Dana-Farber Cancer Institute, Boston, MA,, Boston Children's Cancer and Blood Disorders Center, Boston, MA
Jorge Sierra, Hospital Santa Creu i Sant Pau, Barcelona, Spain
Wendy A. Stock, University of Chicago, Chicago, IL.
Richard M. Stone, Dana-Farber Cancer Institute, Boston, MA
Martin S. Tallman, Lurie Children's Hospital, Chicago, IL
Jürgen Thiele, University of Cologne, Köln, Germany.
Hwei-Fang Tien, National Taiwan University Hospital, Taipei City, Taiwan.
Alexandar Tzankov, Medical University Basel, Basel, Switzerland
Alessandro M. Vannucchi, University of Florence and AOU Careggi, Florence, Italy
Paresh Vyas, University of Oxford, Oxford, United Kingdom
Andrew H. Wei, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia
Olga K. Weinberg, University of Texas Southwestern, Dallas, TX
Mario Cazzola, University of Pavia, Pavia, Italy
Hartmut Döhner, University Hospital Ulm, Ulm, Germany
Ayalew Tefferi, Mayo Clinic, Rochester, MN
Agnieszka Wierzbowska, Medical University of Lodz, Lodz, Poland; and.

Document Type

Article

Publication Date

9-15-2022

Abstract

The classification of myeloid neoplasms and acute leukemias was last updated in 2016 within a collaboration between the World Health Organization (WHO), the Society for Hematopathology, and the European Association for Haematopathology. This collaboration was primarily based on input from a clinical advisory committees (CACs) composed of pathologists, hematologists, oncologists, geneticists, and bioinformaticians from around the world. The recent advances in our understanding of the biology of hematologic malignancies, the experience with the use of the 2016 WHO classification in clinical practice, and the results of clinical trials have indicated the need for further revising and updating the classification. As a continuation of this CAC-based process, the authors, a group with expertise in the clinical, pathologic, and genetic aspects of these disorders, developed the International Consensus Classification (ICC) of myeloid neoplasms and acute leukemias. Using a multiparameter approach, the main objective of the consensus process was the definition of real disease entities, including the introduction of new entities and refined criteria for existing diagnostic categories, based on accumulated data. The ICC is aimed at facilitating diagnosis and prognostication of these neoplasms, improving treatment of affected patients, and allowing the design of innovative clinical trials.

Share

COinS